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Abstract 
 
Early stage evaluation of medical device innovations is important for healthcare decision-makers as 
much as for manufacturers, meaning that a wider application of a basic cost-effectiveness analysis is 
becoming necessary outside the usual expert base of health technology assessment specialists. 
Resulting from an academic-industry-healthcare professional collaboration, a spreadsheet tool is 
described that was designed to be accessible both to professionals in healthcare delivery organisations 
and to innovators in the healthcare technology industry who are non-experts in the field of health 
economics. The tool enables a basic cost-effectiveness analysis to be carried out, using a simplified 
decision-tree model to compare costs and patient benefit for a new device-related procedure with that 
of standard care employing an incumbent device or other alternative. Such a tool is useful to healthcare 
professionals because it enables them to rapidly elucidate the cost-effectiveness of heterogeneous 
innovations by means of the standard quality adjusted life year (QALY) measure of clinical outcome, 
which is intended to be broadly comparable across treatments. For the innovator or manufacturer it 
helps them focus on what is required for future stages of development, in order to fill gaps in the input 
data and so further strengthen their case from a health economics perspective. Results are presented of 
first experiences from deploying the tool on three medical device exemplars, in face-to-face meetings 
of the NHS National Innovation Centre (NIC) along with the innovator or clinical champion. The 
results show that mapping of device-related innovations to the tool is achievable in a short meeting 
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between the NIC and the innovator using expected costs, outcomes data from the literature and 
estimates of ranges for unknown input data. Whilst the result of a simplified analysis is not expected to 
be definitive, the process of reasoning is found to be illuminating for the parties involved, enabling 
innovators to articulate the benefits of their innovations and for all parties to highlight gaps in data and 
evidence that will be required to take the innovation forward. The partnership model of the authors’ 
organisation supports the kind of cooperative design approach that is necessary to produce the kind of 
tool described. 
 
Introduction 
 
Economic evaluation is commonplace in the assessment of therapies involving drugs and medical 
devices. In the UK, in the National Health Service (NHS) context, a cost-effectiveness analysis (CEA) 
is an important component of health technology assessments of treatments that are carried out for 
organisations such as the National Institute for Health and Clinical Excellence (NICE) of England and 
Wales, Quality Improvement Scotland (QIS) and the Department of Health, Social Services and Public 
Safety Northern Ireland (DHSSPNI). The need for increased capacity in the NHS to assess value 
through consideration of both costs and benefits is growing. At the local level, primary and acute 
hospital trusts are already tasked to demonstrate the quality of care through value indicators
1
. Acting on 
the outcomes of the Healthcare Industries Task Force (HITF)
2,3
, the Purchasing and Supply Agency 
(PASA) is now carrying out its own reviews and analysis of economic evidence of products through the 
Centre for Evidence-based Purchasing (CEP). Furthermore, the launch of the National Innovation 
Centre (NIC), another HITF initiative, has made pertinent the need for accessible tools to enable 
decision-makers to assess new healthcare technologies that are disclosed to them. The NIC aims to 
speed up the development of pre-commercial technologies likely to benefit the NHS, and has already 
produced a set of web-based tools to help innovators. In particular, the NIC’s Scorecard tool4 provides 
an automatically generated self-assessment and also allows the innovation to be submitted for review 
by NIC experts if necessary. Scorecard is therefore a gateway to the innovation’s detailed assessment, 
such that if a submission meets an NIC priority, an innovator may be offered a deeper due diligence 
service (covering IP, legal, commercial and financial aspects) with the aim of building a full business 
case. As a measure of the take-up of such tools, in August 2008 the NHS National Innovation Centre 
had received 151 submissions of an idea to its Scorecard tool and 500 out of the 939 registered 
individuals had used it for their own use without submitting it to NIC. 
Resulting from this focus on accelerating the adoption of innovations into the NHS, technology 
businesses that are developing new medical devices for sale in the NHS are being encouraged to think 
about cost-effectiveness analysis at an ever earlier stage in the innovation process. To assist with this, 
the UK-based research programme (Multidisciplinary Assessment of Technology Centre for Healthcare 
(MATCH)
 5
 is collaborating with the NIC to develop and validate a new tool that is intended to be 
suitable for non-expert health economists to carry out, with minimal assistance, a basic cost-
effectiveness assessment of their innovation. The prototype tool was developed within the MATCH 
programme and has recently been made available to all its partners with an expectation for wider 
dissemination. The tool we describe is aimed at early stage cost-effectiveness which would ideally be 
applied after the NIC’s Scorecard gateway. The following sections will describe the function of the 
tool, and present the results of research with three examples where it has been used to determine an 
estimate of cost effectiveness during meetings of MATCH and the NIC together with the participation 
of the innovator or clinical champion. 
Rationale 
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The MATCH programme, which is now in its sixth year since its inception in 2003, has one of its 
major objectives the development and dissemination of methods and tools to support device 
manufacturers and health providers in their assessment of value of innovations in medical technologies. 
Health economics methods, related to the practice of Health Technology Assessment (HTA), are 
central to this approach. Early on in its research, MATCH conducted detailed interviewed with its 
industry partner base (12 interviews over a period of 10 months from March 2004 to January 2005) 
where each was asked about its approach to product development together with a set of questions 
focused on development of a specified product with reference to MATCH’s research themes. This 
enabled MATCH to discover which kinds of decision aids they were using. Few had used health 
economics and none amongst SMEs and start-ups. Subsequently, at MATCH partner conferences, and 
through focussed seminar events to a wider audience of industry and health providers, it became clear 
that greater exposure to HTA methods was needed. Furthermore, as MATCH grew its relationship with 
the UK National Health Service, it became clear that translation of HTA methodology of NICE into a 
decision aid for estimating cost-effectiveness of specific medical device innovations would be useful. 
Out of these relationships emerged the idea for a software tool which is introduced in the following 
sections.  
 
NICE ‘reference case’ for economic evaluations 
 
There are a number of different methods of health economic evaluation that are typically used to assess 
drugs and devices as described by Drummond et al
6
. In order to create consistency in decision making 
between alternatives (where a treatment is assessed against one or more comparators), NICE has 
adopted a ‘reference case’ approach to economic evaluation that has as its basis a cost-utility analysis 
(CUA). A CUA employs the Quality Adjusted Life Year (QALY) as a measure of the health benefits. 
This reference case can be summarised as shown in Table 1
7
. 
 
Table 1 Summary of National Institute for Health and Clinical Excellence (NICE) reference case
7
. 
Element of health technology 
assessment 
Reference case 
Defining the decision problem The scope developed by the Institute 
Comparator Alternative therapies routinely used in the National Health System (NHS) 
Perspective on costs NHS and Personal Social Services (PSS) 
Perspective on outcomes All health effects on individuals 
Types of economic evaluation Cost-effectiveness analysis 
Synthesis of evidence on outcomes Based on a systematic review 
Measure of health benefits Quality-adjusted Life Years (QALYs) 
Description of health states for 
calculation of QALYs 
Health states described using a standardised and validated generic instrument 
Methods of preference elicitation for 
health state valuation 
Choice-based method, for example, time trade-off, standard gamble (not rating 
scale) 
Source of preference data Representative sample of the public 
Discount rate An annual rate of 3.5% on both costs and health effects 
Equity provision 
An additional QALY has the same weight regardless of the other characteristics of 
the individuals receiving the health benefit 
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In addition a sensitivity analysis is recommended to examine to effect of uncertainty in input data. It 
can be seen that the NICE reference case is quite prescriptive, requires expertise to apply it 
comprehensively and will take a significant amount of time to apply. Therefore, in producing its early 
stage tool for use by medical device companies and the National Innovation Centre, MATCH needed to 
ask: 
 
o What features of the NICE reference case are important for an early stage analysis? 
o What kind of tool is most readily accessible to businesses and healthcare professionals who may 
have little prior knowledge of health economics?  
o What features of a tool are required to map the range of innovations presented to the NIC? 
o Will the tool enable an initial assessment to be made in a short time period? 
o Will the results of the analysis focus the innovators in the right direction? 
 
From the detailed interviews with MATCH’s partners it was understood that those involved in product 
development decision processes were familiar with basic ‘office’ tools (word processors and 
spreadsheets) and also that those few that had performed health economics evaluations had used 
Microsoft Excel. It was therefore decided to use the Excel spreadsheet as the basis for a simple tool to 
model cost-utility analyses, with an emphasis on providing graphical output and an element of 
sensitivity analysis. Furthermore the tool would implement the simplest decision model possible with a 
minimum of input variables, to reduce the time and effort to populate the model whilst maintaining 
features that would enable a meaningful comparison to be made. The initial proposal for producing an 
Excel-based tool was made in 2005. The tool was subsequently designed in consultation with health 
economists in MATCH and through listening to participants of MATCH presentations at industry 
events who included manufacturers, health providers, business development executives and 
technologies transfer specialists, where we outlined and discussed health economics methods with 
them. Hands-on experience in producing simple early-stage health economic models alongside industry 
partners had been gained in MATCH through managed projects, which also helped inform the initial 
design. The tool was tested and refined incrementally through its use in educational workshops with 
both industry and NHS partners, from observation and discussion with its initial users and from 
questionnaire feedback at those events. The design and refinement process took place late-2005 to 
early-2007. Use of the tool to support the NHS in assessing innovations, as described in the rest of this 
paper, was managed as a Research Partner project with the National Innovation Centre as a component 
of their subscription to MATCH, whereby a set of innovation exemplars was selected by the NIC and 
agreed. This exemplar project work took place between May and November 2007. 
 
Cost utility analysis 
 
Taking as a comparator the alternative treatment against which an innovation is to be judged, a CUA 
models both the difference in costs and the difference in health effects, where health effects are 
measured in QALYs. Once determined, it is possible to plot the results on a ‘cost-effectiveness plane’ 
as illustrated in Figure 1. The plane is divided into four quadrants which illustrate the four possible 
results of such an analysis: 
 
I  New treatment is more effective and more expensive 
II New treatment is more effective and less expensive 
III New treatment is less effective and less expensive 
IV New treatment is less effective and more expensive 
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The result of any particular comparison is plotted as a single point on the plane. Four points are shown 
on the graph to illustrate hypothetical cases A, B, C and D where the innovation is being compared 
against the incumbent treatment.  
 
Ideally the innovation in question will be both cheaper and more clinically effective than the incumbent 
(case A) so that in principle it has a very good chance of being adopted. However, a more expensive 
innovation may also be considered cost-effective (case B) if there is a health gain which puts the 
innovation beneath the willingness-to-pay threshold (WTP) of the payer, as illustrated by the dotted 
line (where the slope of this line is in units of £ per QALY). A measure of the effectiveness of the 
innovation is then gained by comparing this threshold with the Incremental Cost Effectiveness Ratio 
(ICER) which is defined as: 
 
 
A new treatment is likely to be deemed cost effective by the payer if the ICER is less than the WTP 
threshold. For case C the point is above the WTP threshold, and so the innovation is not likely to be 
considered cost effective. Case D illustrates the problem of uncertainty, where cost-effectiveness may 
be sensitive to parameters in the model, some more than others.  In this case a too high selling price set 
by the manufacturer could affect its viability if that price took it over the WTP threshold. Clearly it will 
be important to examine the effects of other parameters on the location of the point on the cost-
effectiveness plane. It is worth noting that another way of considering the cost-effectiveness from the 
manufacturer perspective is to see whether there is enough headroom between the price of the device 
and the WTP threshold to ensure that the innovation is profitable
8
. 
 
 
 
Figure 1: The Cost Effectiveness Plane 
ICER =  Difference in costs of treatment (∆£) 
Difference in health effects (∆QALYs) 
 
     Difference in Health Effect (∆QALYs) 
+ 
Difference in Costs (∆£) 
+ 
_ 
_ 
I 
New treatment is more effective and 
more expensive 
IV 
New treatment is less effective and 
more expensive 
III 
New treatment is less effective and 
less expensive 
II 
New treatment is more effective and 
less expensive 
A 
B 
C 
D 
     Willingness-to-Pay threshold 
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Basic decision tree model 
 
As a baseline for a simplified early stage model, we notice that modelling is often required for 
diagnosis and treatment of an acute illness where the costs are measured up to a one year time horizon. 
For short term treatments of this kind, cost discounting is not required. QALY data can be obtained 
from the literature, or estimated from published utility values, typically obtained from EuroQoL EQ-5D 
measures
9
, or similar measures such as Health Utilities Index HUI
10
. If it is necessary to apply 
discounting, this is done according to the NICE reference case which currently stipulates a discount 
rate of 3.5% for both costs and QALYs. For chronic conditions a typical approach is to annualise costs, 
and then apply discounting. If the costs and QALYs can be adequately determined, all that remains to 
be found are the probabilities of a patient being treated with the innovation vs. the incumbent, and the 
probabilities of the possible outcomes of the treatment or non-treatment (either ‘healthy’ or ‘not-
healthy’) so that this data can then be used to populate a decision tree, as shown in Figure 2.  
 
For each branch of the decision tree the costs and probabilities are combined to obtain the overall costs  
for the innovation (C1) and for the incumbent (C2). Similarly, utilities and probabilities are combined 
over the appropriate time horizon in order to give QALY measures for the innovation (Q1) and 
incumbent (Q2), therefore allowing the ICER to be calculated as (C1-C2)/(Q1-Q2). In the hypothetical 
example of a comparison shown in figure 2 difference in cost is -£4,745 and the difference in QALYs 
is 0.84, so the ICER is -£5,668.95 per QALY which represents a saving to the NHS for the innovation 
being modelled as well as a health gain. Uncertainty in the ICER can be calculated using the Solver 
component of  Excel to find its overall maximum and minimum over the range of multivariate inputs 
(an alternative, but more involved technique is Monte Carlo analysis). 
 
 
 
 
Figure 2 Basic decision tree model for a Cost Utility Analysis (from Excel spreadsheet chart) 
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The Excel spreadsheet tool 
 
A number of software packages exist to perform decision-tree analysis e.g. TreeAge. However, since 
many professionals are familiar with office tools, as we confirmed in our partner interviews, we aimed 
to reduce the learning curve for early stage cost-utility modelling using a set of Microsoft Excel 
spreadsheets. The features included as individual sheets were: 
 
1. Instructions 
2. Data Input (Figure 3) 
3. Interactive decision tree (Figure 2) 
4. Cost-effectiveness plane chart (Figure 4) 
5. Financials (Figure 5) 
 
Instructions are provided ‘in package’ to enable quick learning of the spreadsheet features and a 
separate user guide document are also provided. For the data input sheet (Figure 3) each parameter is 
entered as a value between a range of possible minimum and maximum values which are also 
specified. To assist with sensitivity analysis, a feature was included whereby the tool’s user can select 
up to 4 parameters (via the tick boxes shown in figure 3) whose values can later be varied on the cost-
effectiveness chart (Figure 4) between their maximum and minimum values and so judge their 
sensitivity effects on the ICER.  
 
The interactive decision tree (shown previously in Figure 2) is populated with the values from the Data 
Input sheet (Figure 3) and on this sheet the user can immediately see the resulting ICER and also 
examine the effect of varying costs and probabilities within their specified ranges. The decision tree is 
essentially a text book health economic model but with the addition of one novel feature that gives an 
extra degree of flexibility. This feature is a percentage cost modifier which allows the modeller to 
estimate an efficiency gain for the innovation, which makes the ‘standard’ treatment cheaper by a 
percentage.  
 
The cost-effectiveness chart (Figure 4) displays the ICER as a single point and the ranges of values 
between maximum and minimum of the cost difference and QALY differences are shown as vertical 
and horizontal bars. It is widely accepted that NICE has an adopted cap of £20,000 to £30,000 per 
quality adjusted life year (QALY) gained, although it does
 
not accept or reject healthcare technologies 
on cost effectiveness
 
grounds alone and there are examples of accepted treatments above this range
11,12
. 
For this reason we include a selectable cap so that £ per QALY thresholds above and below £30,000 
can be plotted, which includes zero to illustrate cost minimisation. Since the range of the ICER depends 
on multiple costs and utilities from the input data, the ‘Solver’ add-in feature of Excel is used to find 
the maximum and minimum values. 
 
Finally, resulting from discussion with industrial partners a break-even analysis sheet (Figure 5) is 
included, where the return on investment can be calculated, given the selling price (or reimbursement), 
a predicted market share, unit manufacturing cost, and non-recoverable expense. For the example 
shown in Figure 5 the innovation provides profit for the company after sales of 5714 units, which 
includes fixed development costs and variable manufacturing cost per unit. 
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Variable Description value Min max 
     
Costs (£)        
Ct Cost of treatment (not including cost of device/test) 7000 5000 10000 
Ct' Cost of not treating (or 'do nothing') 1000 500 1500 
Cth' Cost of further treatment after failed first treatment 8000 5000 10000 
C1d Cost of device/test (not including cost of treatment) 400 200 30000 
C2d Cost of alternative (not including cost of treatment) 500 200 30000 
 Cost modifier for treatment with device/test 50 0 150 
Probabilities (%)        
P1t Probability of treating with device/test 65 60 90 
P2t Probability of treating with alternative 80 60 90 
P1th Probability of healthy outcome after treating with device/test 90 85 95 
P1t'h Probability of healthy outcome after not treating with device/test 80 75 85 
P2th Probability of healthy outcome after treating with alternative 70 65 75 
P2t'h Probability of healthy outcome after not treating with alternative 60 55 65 
        
Utilities        
U1th Utility of Treated with device/test (Healthy) 0.90  0.80  1.00  
U1th' Utility of Treated with device/test (unHealthy) 0.70  0.60  0.80  
U1t'h Utility of not Treated with device/test (Healthy) 0.90  0.80  1.00  
U1t'h' Utility of not Treated with device/test (unHealthy) 0.70  0.60  0.80  
U2th Utility of Treated with alternative (Healthy) 0.90  0.80  1.00  
U2th' Utility of Treated with alternative (unHealthy) 0.70  0.60  0.80  
U2t'h Utility of not Treated with alternative (Healthy) 0.90  0.80  1.00  
U2t'h' Utility of not Treated with alternative (unHealthy) 0.70  0.60  0.80  
        
Time Horizon for Utility (year)       
TU1th Horizon of life of Treated with device/test (Healthy) 10 1 10 
TU1th' Horizon of life of Treated with device/test (unHealthy) 5 1 10 
TU1t'h Horizon of life of not Treated with device/test (Healthy) 10 1 10 
TU1t'h' Horizon of life of not Treated with device/test (unHealthy) 5 1 10 
TU2th Horizon of life of Treated with alternative (Healthy) 10 1 10 
TU2th' Horizon of life of Treated with alternative (unHealthy) 5 1 10 
TU2t'h Horizon of life of not Treated with alternative (Healthy) 10 1 10 
TU2t'h' Horizon of life of not Treated with alternative (unHealthy) 5 1 10 
        
Time Horizon for Cost (year)       
TC1th Horizon of cost of Treated with device/test (Healthy) 1 1 1 
TC1th' Horizon of cost of Treated with device/test (unHealthy) 1 1 1 
TC1t'h Horizon of cost of not Treated with device/test (Healthy) 1 1 1 
TC1t'h' Horizon of cost of not Treated with device/test (unHealthy) 1 1 1 
TC2th Horizon of cost of Treated with alternative (Healthy) 1 1 1 
TC2th' Horizon of cost of Treated with alternative (unHealthy) 1 1 1 
TC2t'h Horizon of cost of not Treated with alternative (Healthy) 1 1 1 
TC2t'h' Horizon of cost of not Treated with alternative (unHealthy) 1 1 1 
        
Discount rate (%)        
D Discount rate 3.5 0 6 
Figure 3  Data input for basic decision tree model (from Excel spreadsheet) 
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Figure 4 Cost-effectiveness chart with scroll bars allowing ICER sensitivity to selected input data to be 
examined (from Excel spreadsheet) 
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Market Projections      
Market volume  25000     
Market Share anticipated (%) 30     
Number of units sold  7500     
   
 
    
Price per unit (£)  400    
 200  2,500   
       
Revenue (£)  3000000     
Cost of Revenue       
Variable Unit Cost  225     
Fixed  1000000     
Total  2687500     
        
Profit  312500     
        
        
Break Even Point  5714 (sales volume)   
% share of market required 23     
            
Figure 5 Break even analysis (from Excel spreadsheet, Financials tab) 
 
Exemplar studies 
 
In order to investigate the potential of the tool, three exemplars were chosen to be conducted in 
collaboration with the NIC and the innovator or clinical champion of the medical device. All of the 
exemplars are part of treatment for diseases that are prevalent in the UK. In the following, for reasons 
of commercial confidentiality it is not the intention either to describe the innovation in detail or specify 
device costs, nor to provide an answer for cost-effectiveness or discuss the validity of results, but rather 
to describe the experience of using the tool. 
 
1) Saturation driven oxygen therapy (SDOT) 
 
Oxygen therapy involves providing patients with a prescribed flow of oxygen from a cylinder or 
concentrator. It is a standard treatment for patients with respiratory conditions, such as emphysema, 
cystic fibrosis and others, providing improvement in cardiac function, exercise ability and quality of 
life. However, the existing treatment is not responsive to variations in the patient’s oxygen demand, 
resulting in periods of insufficient oxygenation that may accelerate disease progression and worsening 
cardiovascular health. Saturation Driven Oxygen Therapy (SDOT) is a system developed by a UK 
company that automatically adjusts the oxygen flow to match the patient’s measured demand. It is 
fitted to an existing oxygen delivery system. The flow control system is intended to improve health by 
avoiding periods of insufficient oxygenation, however it also reduces demands on GPs for setting 
prescription levels, and users have suggested it reduces patient anxiety about home treatment. SDOT is 
also expected to reduce the time required for assessing a patient under NICE guidelines, since some of 
the time of consultation is taken up with a series ‘shuttle walks’ where the patient is asked to walk 
between two points and oxygen saturation is measured using a pulse oximeter. It may take 30-40 
minutes of shuttle walks before an average oxygen flow setting is determined, whereas the SDOT 
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system, based on continuous pulse oximeter measurement, should assist with the setting and then 
maintain the correct flow automatically. 
 
The costs and benefits of SDOT were modelled using the decision tree spreadsheet during a 3 hour 
session at the NIC in consultation with the innovator. Some costs and probabilities were available from 
recent clinical trials, and a utility value for a patient with emphysema from a published reference on 
chronic conditions was used as the baseline for health benefits. The innovation requires an additional 
annual cost on top of the existing therapy that is represented in the first branch level of the upper 
‘innovation’ decision tree. The added cost in the first branch of the lower ‘incumbent’ tree, for 
conventional oxygen therapy, is zero. In the second level, a combined consultation, assessment and 
treatment cost is entered, and cost of non-treatment (consultation only) is also entered. An appropriate 
cost modifier was entered for SDOT based on an assumption that the assessment time is reduced 
because it is not necessary to spend time finding the correct oxygen level for the patient, as discussed 
above. Finally a ‘not healthy’ cost was entered to account for the possibility of A&E admission due to 
exacerbation or disease progression. Estimates of probabilities and utilities were entered using the 
baseline emphysema utility value modified by reasoning about the health benefits of SDOT (e.g. 
reduction in periods of excessive/insufficient blood oxygen). 
 
From the values entered, one is able to infer that the additional cost of SDOT may be balanced by the 
benefits. By running the Solver component of the Excel spreadsheet for appropriate input ranges of 
costs, probabilities and utilities, it was revealed that overall cost differences between SDOT and 
conventional oxygen therapy vary to the extent that in the very worst case, the ICER could possibly go 
over a WTP threshold of £30,000 per QALY. However this would only be for substantially higher 
device and treatment costs, lower costs of dealing with failed treatments, and the smallest QALY gain. 
In the best case, using SDOT could result in a substantial cost saving for a modest improvement in 
clinical benefit. Since many of the values are estimates, it is important to stress once again that it is not 
the precise value of the ICER that is important, but rather the reasoning involved in mapping the 
problem to the simplified tree and from the process of examining the uncertainties. 
 
According the innovator. the main questions identified by the modelling SDOT in the tool were: 
 
Q1. What range of consultant and GP prescribing time, where saved by use of SDOT, justify value for 
money when used as a diagnostic device? 
 
Q2. Can sufficiently accurate utility values be obtained from the literature to justify the model’s claim 
for improved benefit, or what trial design will support this? 
 
Q3. What are the additional costs to the NHS associated with non-optimal delivery of oxygen therapy, 
and the true probability of A&E admission following poor quality home treatment? 
 
Answers to these questions informed further development and evaluation of the device, and also 
identified new market opportunities for the company. 
 
2) Optical blood glucose monitoring 
The importance of good control of blood glucose level in diabetes is well known and this is most 
commonly achieved by taking a blood sample from the finger using a lancet (finger stick) and then 
measuring it on a test strip with a blood glucose meter. One problem for the user associated with the 
technique is that it is invasive. Repeated perforation of the finger (or alternative test site) causes skin 
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and nerve damage and the process is not pain free. For this and a variety of other reasons, many 
patients do not test themselves as often as recommended. By removing the need to sample blood 
directly, the innovation of non-invasive blood glucose metering aims to overcome these problems. 
Such a device is being developed by a UK company, using an optical technique that measures blood 
glucose level in the eye. 
As for the first exemplar, the innovation was compared with a conventional treatment, in this case 
using lancet, test strip and blood glucose meter as the incumbent. In the case of the comparator the 
meter itself is generally provided free of charge by the manufacturer and the annual per patient cost is 
the price of the consumables (lancets and test strips) estimated as an annual cost averaged over all 
patients. The cost of the new meter was entered as a modification of the annual consumables cost. It 
was not necessary to include the cost of insulin therapy resulting from testing on the basis that this is 
arguably the same for both arms of the comparison (dependent on proportion of Type 1 and Type 2 
diabetics and degree of insulin use). An average cost of treating the complications of diabetes was 
entered. The probabilities were estimated such that the probability of healthy outcome was greater for 
the innovation, due to increased compliance. A baseline utility for a patient with diabetes mellitus was 
obtained from the literature. A decision tree model resulted from this mapping, much of the meeting 
time being taken in discussing the utility values and probabilities, and how utilities change with disease 
progression. 
In this example, it was assumed that the main economic case for an optical meter rests on the annual 
cost saving on consumables and improved compliance that results in a higher proportion of healthy 
patients. As for the first exemplar, it will be necessary to fully justify the input data values chosen, and 
apply discounting so that the ‘not healthy’ costs and QALYs are compounded into their present values, 
since the expected health gains from better diabetes management will not all be realised in the short 
term. 
 
3) Varicose vein closure techniques 
 
There are a number of techniques for varicose vein treatment using endovenous ablation to close the 
veins by chemical, laser or radio-frequency (RF) means. As well as the choice of technique, treatments 
vary as to whether the patient undergoes local anaesthesia (LA) or general anaesthesia (GA) and 
whether one or two legs are treated in the same session (unilateral or bilateral). These alternative 
endovenous treatments are currently undergoing close scrutiny in the UK with the NIC, CEP and HTA 
Programme all involved with evaluation. The potential for cost saving, together with higher throughput 
by delivery outside of secondary care, is of particular interest for the NHS 18 Week Programme. 
 
For the purposes of modelling with a health economics tool, we can consider comparison of several 
patient pathways. Two such pathways were determined in a meeting with a surgeon who was carrying 
out clinical research into the alternative endovenous treatments. Firstly, it is necessary to model the 
cost effectiveness of unilateral varicose veins therapy carried out under LA using laser or RF, but with 
a probability of some patients requiring a second treatment. According to the surgeon who participated 
in the discussions with NIC, a proportion of his eligible patients elect for treatment under LA which is 
quicker that with GA. However therapy may be painful from heating of tissue and if vein-stripping is to 
be carried out in addition to the endovenous treatment, so this could limit the amount of vein treated in 
a single treatment session if carried out under LA.. Secondly it is necessary to model the cost 
effectiveness model of unilateral varicose vein therapy performed using endovenous ablation under 
GA. A different proportion of patients prefer this option or are best served by it for anatomical reasons. 
This provision requires several essential staff in theatre and recovery. In both cases the incumbent 
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treatment can be vein stripping or chemical sclerotherapy. The meeting was concluded with a 
commitment to obtain further cost data in order to fully populate the decision trees. Even though the 
model was not fully completed during the meeting between NIC and the surgeon, the framing of 
discussions in terms of decision trees was instrumental in increasing understanding of the NIC about 
the alternatives and factors impacting on cost-effectiveness. Subsequent discussions with the 
manufacturer of the RF system also yielded some differences of option within the surgeon community 
with respect to treatment under LA versus GA. The majority of Trusts using this particular system are 
already using LA, including bilateral treatments, and most are moving to an outpatient setting. This 
subsequent dialogue also increased understanding by NIC of differences between the laser and RF 
alternatives.   
 
Conclusions 
 
With an increasing need to identify additional spending with metrics of patient benefit, the wider 
application of basic cost-effectiveness analysis has become necessary outside the usual expert base of 
health technology assessment specialists. In the context of the findings of the UK Health Industries 
Task Force, that a better assessment of value is required to bring new health technologies into the 
National Health Service, the tool described is seen to be facilitating a common understanding of value 
between healthcare decision-makers and medical device developers or clinician ‘champions’ who are 
amongst the first adopters of newly marketed devices.  
 
Further exemplar work is needed to examine the generalisability of the tool in terms of number and 
depth of decision tree branches, balanced with a requirement to keep the model simple for non-expert 
use, and in the knowledge that data for a more complex model will be limited at the early stage of an 
innovation’s development or deployment. As stated repeatedly, the tool is not intended to replace the 
need for a full NICE appraisal using a more complete data set, accepting that limited data will be the 
norm for early stage decisions. However more work needs to be done to examine the sensitivity to 
estimated data ranges and especially to research the effect on decisions from the making of optimistic 
or pessimistic estimates.  
 
Conducting these exemplar studies with the tool on real users during its development prompted 
discussion about the ‘percentage cost modifier parameter’. The rationale for inclusion of the feature 
was based on an example of a diagnostic device designed to assess burns by means of blood flow 
measurement, where the treatment is a skin graft. If the innovation resulted in better assessment of the 
area in need of grafting, it was argued that this could be modelled as an efficiency saving in the 
treatment and therefore cost of treatment could be reduced accordingly. However, for general use it is 
perhaps too tempting to use it as a ‘fudge factor’ to reduce the relative cost of the innovation. We have 
now decided to remove the feature and the user should enter cost savings to treatments directly. 
 
A major lesson learnt from the exemplar work is that lack of hard data is not a barrier to mutual 
understanding of value at the early stage of development or deployment of a medical technology 
innovation. We also found that data may exist but not be readily available, which suggests that wider 
deployment of the tool would ideally be supported by an accessible repository of data for the purposes 
of health economics evaluation. Most importantly the tool was developed in close partnership with its 
users. The close academic-industry-healthcare professional linkage facilitated by MATCH supports and 
actively promotes this kind of cooperative design approach. 
 
All of the focussed evaluation meetings were carried out over a half day period. However, some 
preparation is needed by all parties. Since conducting these exemplars, and after further consultations 
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with partners in the medical devices industry, we have identified that an introduction to health 
economics, data sources and some hands-on training with the tool prior to the evaluation meeting 
would be beneficial. MATCH therefore decided to launch a series of tool workshops through the UK-
wide Medilink network which brings together medical manufacturing and distribution companies, 
hospitals and universities to stimulate innovation on a regional basis. This is taking place alongside a 
new phase of exemplar studies with both NIC and PASA.  
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